Document Detail


Anti-hypertensive effects of probenecid via inhibition of the α-adrenergic receptor.
MedLine Citation:
PMID:  22180356     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Probenecid has long been used in the treatment of gout. Its anti-gout mechanisms consist of uric acid reuptake inhibition and the consequent facilitation of uric acid excretion. In the present study, we investigated whether probenecid could exert an anti-hypertensive effect in spontaneously hypertensive rats (SHR). The noninvasive indirect tail cuff method was employed to measure blood pressure and heart rate. The administration of probenecid (50 mg/kg, ip) induced a significant systolic blood pressure (SBP) decrease, from 167 mmHg to 141 mmHg, within 120 min. In contrast, probenecid had little effect on normotensive control Wistar Kyoto rats (WKY). The anti-hypertensive effects of probenecid are almost as potent as those of atenolol. In a further exploration of the anti-hypertensive mechanisms of probenecid, its effects on phenylephrine-induced blood vessel contraction were tested. Our results suggest that probenecid significantly inhibited the contractions of rat aorta. This effect was also observed with endothelium-removed rat aorta, suggesting that probenecid can directly interact with the α-adrenergic receptor. Moreover, probenecid inhibited the α-adrenergic-receptor-mediated activation of ERK I/II in MC3TC-E1 cells. Therefore, our results indicate that probenecid might alleviate high blood pressure in SHR via inhibition of the α-adrenergic receptor and ERK I/II.
Authors:
Jin Baek Park; Sung-Jin Kim
Related Documents :
21844826 - Distinct cardioprotective effects of 17β-estradiol and dehydroepiandrosterone on press...
22274746 - Psychological symptoms and blood pressure among rural-dwellers.
7329986 - Postsynaptic adrenergic unresponsiveness in hypotensive haemodialysis patients.
19653576 - Flying experience and cardiovascular response to rapid head-up tilt in fighter pilots.
24519426 - Supersonic shear wave elastography for the in vivo evaluation of trans-epithelial corne...
23355126 - Reduction of cardiovascular risk through angiotensin ii type 1 receptor antagonism : fo...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pharmacological reports : PR     Volume:  63     ISSN:  1734-1140     ISO Abbreviation:  Pharmacol Rep     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-12-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101234999     Medline TA:  Pharmacol Rep     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  1145-50     Citation Subset:  IM    
Affiliation:
Department of Pharmacology and Toxicology, Metabolic Diseases Research Laboratory, School of Dentistry, Kyung Hee University, Seoul, Korea. kimsj@khu.ac.kr.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  IFN-? suppresses the high glucose-induced increase in TGF-?1 and CTGF synthesis in mesangial cells.
Next Document:  Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease...